ED Treatment Gaps Persist for Pediatric Atopic DermatitisByChristopher G. Bunick, MD, PhD,Shannon Heaning, Content AssociateJuly 18th 2026
Precision Medicine in Atopic Dermatitis: Current Challenges and Future DirectionsByChristopher G. Bunick, MD, PhD,Shannon Heaning, Content AssociateJuly 15th 2026
Soficitinib (ICP-332) Meets Primary Endpoint in Phase 3 Trial for Moderate to Severe ADByMarie Bosslett, Assistant EditorJuly 15th 2026
Skin & Psych: Addressing Psychological Stress in Pediatric Atopic Dermatitis CareByPatricia Delgado, DNP, AGPCNP, DCNP, PMHNP,Peter Lio, MD,Shannon Heaning, Content AssociateJuly 14th 2026
GX-03 Demonstrates Encouraging Safety as Development ContinuesByBradley Burnam,Shannon Heaning, Content AssociateJuly 10th 2026